Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract—Case Study: Tenapanor
Konstantinos Stamatopoulos, Nena Mistry, Nikoletta Fotaki, David B. Turner, Brandon Swift · 2023
Read Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract—Case Study: Tenapanor by Konstantinos Stamatopoulos, Nena Mistry, Nikoletta Fotaki, David B. Turner, Brandon Swift (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10747343.txt.
Description
Konstantinos Stamatopoulos and co-authors build a body-based computer model for a gut drug that barely enters the blood. The drug, tenapanor, blocks a sodium swap channel in the gut and treats constipation tied to irritable bowel syndrome. Less sodium uptake leaves more water in the gut, which speeds waste along.
The model treats food sodium as the party acted on, and the drug as the actor that cuts its uptake. Meals were built in, since eating wakes the same channel. The model matched sodium in stool and urine of healthy users within a tight range. It also helped explain why dose timing against meals matters, and compared two forms of the drug.
Catalog record
| CREATOR | Konstantinos Stamatopoulos, Nena Mistry, Nikoletta Fotaki, David B. Turner, Brandon Swift |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |